Shares of Immunome, Inc. (NASDAQ:IMNM – Get Free Report) have received an average rating of “Buy” from the seven research firms that are currently covering the company, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $29.80.
A number of brokerages have weighed in on IMNM. JPMorgan Chase & Co. assumed coverage on shares of Immunome in a report on Tuesday, April 30th. They issued an “overweight” rating and a $24.00 price target for the company. Wedbush restated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Tuesday, May 14th. Guggenheim initiated coverage on Immunome in a research note on Monday, April 15th. They issued a “buy” rating and a $35.00 target price on the stock. Finally, Piper Sandler started coverage on Immunome in a research note on Friday, May 31st. They set an “overweight” rating and a $27.00 price target for the company.
Check Out Our Latest Research Report on Immunome
Immunome Trading Up 0.8 %
Immunome (NASDAQ:IMNM – Get Free Report) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.46. The firm had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $4.00 million. Immunome had a negative net margin of 1,829.44% and a negative return on equity of 37.33%. On average, research analysts expect that Immunome will post -1.45 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, Director Jean Jacques Bienaime purchased 2,000 shares of the firm’s stock in a transaction dated Tuesday, May 21st. The stock was bought at an average price of $13.57 per share, with a total value of $27,140.00. Following the completion of the purchase, the director now owns 9,615 shares in the company, valued at approximately $130,475.55. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 8.60% of the company’s stock.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the business. Redmile Group LLC increased its position in Immunome by 26.0% in the first quarter. Redmile Group LLC now owns 4,889,554 shares of the company’s stock worth $120,674,000 after buying an additional 1,010,139 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Immunome by 113.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,245,673 shares of the company’s stock worth $55,425,000 after buying an additional 1,194,451 shares during the last quarter. Vanguard Group Inc. raised its position in Immunome by 16.1% during the first quarter. Vanguard Group Inc. now owns 2,019,738 shares of the company’s stock valued at $49,847,000 after purchasing an additional 279,712 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Immunome by 10.6% in the 1st quarter. Janus Henderson Group PLC now owns 1,538,414 shares of the company’s stock worth $37,957,000 after purchasing an additional 146,943 shares in the last quarter. Finally, Avidity Partners Management LP bought a new position in Immunome during the fourth quarter valued at approximately $14,268,000. 44.58% of the stock is owned by institutional investors.
Immunome Company Profile
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Further Reading
- Five stocks we like better than Immunome
- How to Invest in Blue Chip Stocks
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Why is the Ex-Dividend Date Significant to Investors?
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- How to Choose Top Rated Stocks
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.